US stocks today: Nasdaq, S&P 500 end lower on renewed AI growth worries ahead of big tech earnings
U.S. stocks retreated from record highs as concerns over the AI boom and OpenAI’s performance weighed on tech shares. Investors are anticipating quarterly results from major AI firms, while the Federal Reserve’s stance on inflation amid soaring crude prices remains a key focus.
Peak XV exits One MobiKwik Systems in Rs 130 crore block deal: Report
Venture capital firm Peak XV Partners has exited Indian fintech One MobiKwik Systems. The firm sold its stake for over Rs 130 crore. This exit follows One MobiKwik’s significant milestone. The Reserve Bank of India approved its application for a Non-Banking Financial Company license. This approval allows the company to launch a new lending arm.
Broader markets rally! These 10 smallcap stocks jumped up to 57% in April so far
Indian stock markets have made a partial recovery in April so far, following the incessant March selloff triggered by the onset of the Iran-US war. Interestingly, broader markets have outperformed benchmarks during this period, with Nifty Smallcap 250 index rallying around 17% so far this month, eclipsing Nifty’s 8% surge in the same period. Here […]
Sun Pharma-Organon deal: How a $12-billion merger will reshape India’s pharma landscape
Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The deal leverages Organon’s strengths in women’s health, biosimilars, and established brands, aiming for significant growth despite geopolitical concerns. Integration plans and manageable debt are key to the strategic move.
Reliance share price target hiked to Rs 1,910: Why Goldman, CLSA, and Morgan Stanley are betting big
Reliance Industries is gaining traction as Goldman Sachs raises its target price, with global brokerages predicting significant upside despite a recent 13% stock dip. Analysts are optimistic about the oil-to-chemicals business recovery, the impending Jio IPO, and Reliance’s integrated downstream advantage in a tightening market.
Tata Steel shares jump 2% to fresh record high: What’s driving the gains?
Tata Steel shares surged to a new record high on Tuesday. This rise followed the Odisha High Court’s decision to quash state government demand notices totaling nearly Rs 4,314 crore. The company had contested these notices related to its Sukinda Chromite Block.
Varun Beverages shares jump 9% in 3 days. Why Jefferies, Motilal, and others are bullish after Q4 results?
Varun Beverages shares extended gains after strong Q1 CY2026 results, with double-digit growth in profit, revenue, and volumes. Brokerages remain bullish, citing robust demand, margin resilience, and growth from international markets, while competition and input costs remain key monitorables for the company.
Coal India shares rise over 3% after Q4 results: What Jefferies, Morgan Stanley, HSBC and others are saying
Coal India’s shares surged following a stable March quarter performance, with a 12% rise in consolidated profit after tax to Rs 10,908 crore. Revenue also climbed 6% to Rs 46,490 crore, driven by better realisations. Analysts remain divided, with Jefferies and Motilal Oswal maintaining Buy ratings, while Morgan Stanley and HSBC suggest holding the stock.
India’s power market entering a storage-led transformation phase: Apoorva Bahadur
India’s electricity system faces a critical juncture as soaring summer demand outstrips generation flexibility. While renewables meet daytime needs, evening peaks highlight a significant storage gap. Experts warn of potential shortages if storage capacity doesn’t scale rapidly to balance the grid and capture emerging profit opportunities.
Stock picking key as auto, banks face near-term headwinds: Sandip Sabharwal
Market expert Sandip Sabharwal maintains a constructive long-term outlook but stresses selectivity due to near-term risks like rising input costs and competition. He favors midcaps and selective smallcaps, seeing opportunities in consumer durables, while cautioning on financials and quick commerce. Large pharma deals require careful integration and valuation assessment.